Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 9/30/2015 | 6/30/2015 | 3/31/2015 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.02 | -0.11 |
| FCF Yield | 18.14% | 27.52% | -0.71% | -27.37% |
| EV / EBITDA | -17.98 | 71.75 | -37.49 | -8.69 |
| Quality | ||||
| ROIC | 4.81% | 0.24% | 5.42% | 20.34% |
| Gross Margin | 60.20% | 68.16% | 60.16% | 48.42% |
| Cash Conversion Ratio | -0.13 | -0.56 | 0.05 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.04% | -16.69% | -15.76% | -9.94% |
| Free Cash Flow Growth | -42.11% | 702.56% | 98.50% | -716.49% |
| Safety | ||||
| Net Debt / EBITDA | -16.64 | 65.68 | -23.65 | -4.25 |
| Interest Coverage | -1.54 | -0.06 | -1.39 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 5.56 | 4.02 | 4.28 | 6.44 |
| Cash Conversion Cycle | -278.31 | -320.52 | -290.94 | -318.14 |